Nature Communications (Sep 2021)
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
- Johannes Bloehdorn,
- Andrejs Braun,
- Amaro Taylor-Weiner,
- Billy Michael Chelliah Jebaraj,
- Sandra Robrecht,
- Julia Krzykalla,
- Heng Pan,
- Adam Giza,
- Gulnara Akylzhanova,
- Karlheinz Holzmann,
- Annika Scheffold,
- Harvey E. Johnston,
- Ru-Fang Yeh,
- Tetyana Klymenko,
- Eugen Tausch,
- Barbara Eichhorst,
- Lars Bullinger,
- Kirsten Fischer,
- Martin Weisser,
- Tadeusz Robak,
- Christof Schneider,
- John Gribben,
- Lekh N. Dahal,
- Mathew J. Carter,
- Olivier Elemento,
- Dan A. Landau,
- Donna S. Neuberg,
- Mark S. Cragg,
- Axel Benner,
- Michael Hallek,
- Catherine J. Wu,
- Hartmut Döhner,
- Stephan Stilgenbauer,
- Daniel Mertens
Affiliations
- Johannes Bloehdorn
- Department of Internal Medicine III, University of Ulm
- Andrejs Braun
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
- Amaro Taylor-Weiner
- Broad Institute of Harvard and MIT
- Billy Michael Chelliah Jebaraj
- Department of Internal Medicine III, University of Ulm
- Sandra Robrecht
- Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne
- Julia Krzykalla
- Division of Biostatistics, German Cancer Research Center
- Heng Pan
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine
- Adam Giza
- Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne
- Gulnara Akylzhanova
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
- Karlheinz Holzmann
- Genomics Core Facility, Ulm University
- Annika Scheffold
- Department of Internal Medicine III, University of Ulm
- Harvey E. Johnston
- Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton
- Ru-Fang Yeh
- Biostatistics, Genentech Inc.
- Tetyana Klymenko
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
- Eugen Tausch
- Department of Internal Medicine III, University of Ulm
- Barbara Eichhorst
- Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne
- Lars Bullinger
- Medical Clinic for Hematology, Oncology and Tumor Biology, Charité University Hospital
- Kirsten Fischer
- Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne
- Martin Weisser
- Roche Pharma Research and Early Development
- Tadeusz Robak
- Department of Hematology, Medical University of Lodz
- Christof Schneider
- Department of Internal Medicine III, University of Ulm
- John Gribben
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
- Lekh N. Dahal
- Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton
- Mathew J. Carter
- Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton
- Olivier Elemento
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine
- Dan A. Landau
- Cancer Genomics and Evolutionary Dynamics, Weill Cornell Medicine
- Donna S. Neuberg
- Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Mark S. Cragg
- Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton
- Axel Benner
- Division of Biostatistics, German Cancer Research Center
- Michael Hallek
- Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne
- Catherine J. Wu
- Broad Institute of Harvard and MIT
- Hartmut Döhner
- Department of Internal Medicine III, University of Ulm
- Stephan Stilgenbauer
- Department of Internal Medicine III, University of Ulm
- Daniel Mertens
- Department of Internal Medicine III, University of Ulm
- DOI
- https://doi.org/10.1038/s41467-021-25403-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
Chronic lymphocytic leukemia has been studied using multiple levels of omics data. Here, the authors use exome sequencing, SNP, protein and gene expression data to identify distinct biologic tumor subtypes with heterogeneous prognostic impact after chemo- or immunochemotherapy.
